Skip to content

Effect of high-flow nasal cannula oxygen therapy on exercise capacity in patients with Idiopathic Pulmonary Fibrosis

Effect of high-flow nasal cannula oxygen therapy on exercise capacity in patients with Idiopathic Pulmonary Fibrosis - Effect of high-flow nasal cannula oxygen therapy in patients with Idiopathic Pulmonary Fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000038945
Enrollment
26
Registered
2019-12-20
Start date
2019-12-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

Arm A A symptom-limited incremental exercise tests were carried out on cycle-ergometer with ambient air. Next time, patient performed constant-load symptom-limited exercise test in a random order arm

Sponsors

Kobe City Medical Center General Hospital Department of Rehabilitation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient aged =<40 years at informed consent 2. Patient with idiopathic pulmonary fibrosis diagnosed according to the diagnostic criteria of INPULSIS trial and 2011 or 2018 ATS/ERS/JRS/ALAT guideline 3. Patients who have exercise induced oxygen desaturation (SpO2 <90%) during 6 minute walking test on ambient air 4. Patient with dyspnea on exercise (1 =< mMRC =< 3) 5. Stable patients without any infection nor acute exacerbation within 3 months 6. Patients who can see a doctor's visit to take outpatient rehabilitation program 7. Patients who can adequately answer the questionnaire about subjective symptom 8. Written informed consent is obtained

Exclusion criteria

Exclusion criteria: 1. Patients with connective tissue disease, neuromuscular disease or orthopedic problem and other disease which may affect to exercise assessment and requires exercise limitation 2. Patients who have pulmonary hypertension, according to WHO guideline [I-II => NYHA and 25mmHg => mean pulmonary arterial pressure (40mmHg => TRPG)] and use a pulmonary vasodilator 3. Using an anti-arrhythmic drug 4. Using long-term oxygen therapy 5. Patients who cannot be evaluated by 6 minute walk test for any reason 6. Patients who are judged by the investigator as not adequate to participate in this study 7. History of malignant disease within 3 years

Design outcomes

Primary

MeasureTime frame
Endurance time of exercise

Secondary

MeasureTime frame
1. Dyspnea (modified Borg Scale) 2. Fatigue of lower limb (modified Borg Scale) 3. Desaturation (SpO2) 4. Heart rate 5. Blood pressure 6. Patient comfort to each device (Visual Analog Scale)

Countries

Japan

Contacts

Public ContactJumpei Harada

Kobe City Medical Center General Hospital Department of Rehabilitation

jumpei_harada@kcho.jp078-302-4321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026